Description

Prenesa (perindopril tert-butylamine) tablets 8 mg. №30

Ingredients

Active ingredient: Perindopril tert-butylamine 8 mg

Dosage

Recommended dosage: The usual dose is 8 mg taken once daily. Dosage may be adjusted based on individual response.

Indications

Indicated for: Hypertension, heart failure, and post-myocardial infarction.

Contraindications

Contraindications include: History of angioedema related to previous ACE inhibitor therapy, hereditary or idiopathic angioedema, severe renal impairment.

Directions

Administration: Take the tablet orally with or without food. Swallow the tablet whole with a glass of water.

Scientific Evidence

Perindopril, the active ingredient in Prenesa, is an ACE inhibitor that works by blocking the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced aldosterone secretion. Clinical trials have shown that perindopril is effective in lowering blood pressure, improving cardiac function, and reducing cardiovascular events. A study by Fox et al. (2003) demonstrated the benefits of perindopril in reducing the risk of heart failure and mortality post-myocardial infarction.

Additional Information

It is important to monitor renal function and potassium levels regularly during treatment with perindopril. Common side effects may include dizziness, cough, and hypotension. Patients should avoid using potassium supplements or salt substitutes containing potassium without medical advice.

Pharmacological Effects

Perindopril exerts its pharmacological effects by inhibiting the angiotensin-converting enzyme (ACE), thereby reducing the production of angiotensin II. This results in vasodilation, decreased aldosterone secretion, and ultimately leads to reduced blood pressure and improved cardiac function. Additionally, perindopril has been shown to have beneficial effects on endothelial function and vascular remodeling, contributing to its cardioprotective properties.

Clinical Trials and Comparative Effectiveness

Clinical trials have demonstrated the efficacy of perindopril in reducing cardiovascular events and improving outcomes in patients with hypertension, heart failure, and post-myocardial infarction. Comparative studies have shown that perindopril is equally effective or even superior to other ACE inhibitors in terms of cardiovascular protection and tolerability. For instance, the EUROPA trial compared perindopril with placebo in patients with stable coronary artery disease and showed a significant reduction in cardiovascular events with perindopril treatment.

References:

• Fox KM, et al. (2003). Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 362(9386), 782-788.